GX-19N

DRUG3 trials

Sponsors

Genexine, Inc.

Conditions

SARS-CoV-2SARS-CoV2 Infection

Phase 1

Safety and Immunogenicity Study of GX-19N, a COVID-19 Preventive DNA Vaccine in Healthy Adults

CompletedNCT04715997

Genexine, Inc.SARS-CoV-2

Start: 2020-12-30End: 2022-04-19Updated: 2025-08-20

Safety and Immunogenicity of GX-19N, a COVID-19 Preventive DNA Vaccine in Elderly Individuals

CompletedNCT04915989

Genexine, Inc.SARS-CoV-2

Start: 2021-02-16End: 2022-04-01Updated: 2024-03-01

Phase 2

Evaluation of Efficacy, Safety and Immunogenicity of GX-19N in Healthy Individuals Who Have Received COVID-19 Vaccines

WithdrawnNCT05067946

Genexine, Inc.SARS-CoV2 Infection

Start: 2021-10-31End: 2023-10-31Updated: 2022-04-12

Related Papers

Safety and immunogenicity of two recombinant DNA COVID-19 vaccines containing the coding regions of the spike or spike and nucleocapsid proteins: an interim analysis of two open-label, non-randomised, phase 1 trials in healthy adults.

2022-02-0847 citations